Last reviewed · How we verify
Carboplatin (Induction)
Carboplatin (Induction) is a Platinum-based chemotherapy agent Small molecule drug developed by Celgene. It is currently in Phase 3 development for Ovarian cancer (induction therapy), Non-small cell lung cancer, Small cell lung cancer.
Carboplatin is a platinum-based chemotherapy agent that forms DNA crosslinks, preventing cancer cell replication and inducing cell death.
Carboplatin is a platinum-based chemotherapy agent that forms DNA crosslinks, preventing cancer cell replication and inducing cell death. Used for Ovarian cancer (induction therapy), Non-small cell lung cancer, Small cell lung cancer.
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas). -
Oncology Phase 3 boost
+3.0pp
Oncology Phase 3 trials have higher approval rates (~61%) than the cross-industry average due to clearer endpoints and FDA oncology pathway.
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Carboplatin (Induction) |
|---|---|
| Sponsor | Celgene |
| Drug class | Platinum-based chemotherapy agent |
| Target | DNA |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Carboplatin binds to DNA and forms interstrand and intrastrand crosslinks, disrupting DNA replication and transcription. This leads to apoptosis in rapidly dividing cancer cells. It is a second-generation platinum compound designed to have a more favorable toxicity profile compared to cisplatin while maintaining anti-tumor efficacy.
Approved indications
- Ovarian cancer (induction therapy)
- Non-small cell lung cancer
- Small cell lung cancer
- Head and neck cancer
- Testicular cancer
Common side effects
- Thrombocytopenia
- Neutropenia
- Anemia
- Nausea and vomiting
- Nephrotoxicity
- Ototoxicity
- Peripheral neuropathy
Key clinical trials
- A Study of the Drugs Selumetinib vs. Carboplatin and Vincristine in Patients With Low-Grade Glioma (PHASE3)
- Durvalumab as Consolidation for Patients LS-SCLC (PHASE2)
- Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma (PHASE3)
- Evaluating the Addition of the Immunotherapy Drug Atezolizumab to Standard Chemotherapy Treatment for Advanced or Metastatic Neuroendocrine Carcinomas That Originate Outside the Lung (PHASE2, PHASE3)
- Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer (PHASE2)
- Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023] (PHASE3)
- Veliparib With or Without Radiation Therapy, Carboplatin, and Paclitaxel in Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery (PHASE1, PHASE2)
- Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Carboplatin (Induction) CI brief — competitive landscape report
- Carboplatin (Induction) updates RSS · CI watch RSS
- Celgene portfolio CI
Frequently asked questions about Carboplatin (Induction)
What is Carboplatin (Induction)?
How does Carboplatin (Induction) work?
What is Carboplatin (Induction) used for?
Who makes Carboplatin (Induction)?
What drug class is Carboplatin (Induction) in?
What development phase is Carboplatin (Induction) in?
What are the side effects of Carboplatin (Induction)?
What does Carboplatin (Induction) target?
Related
- Drug class: All Platinum-based chemotherapy agent drugs
- Target: All drugs targeting DNA
- Manufacturer: Celgene — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Ovarian cancer (induction therapy)
- Indication: Drugs for Non-small cell lung cancer
- Indication: Drugs for Small cell lung cancer
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing